(RTTNews) - Amgen Inc. (AMGN) Tuesday announced positive topline data from the Phase 3 MINT study evaluating Uplizna for the treatment of adults with generalized myasthenia gravis, a rare autoimmune disorder. The study met its primary goal.
The primary endpoint of the study was change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score, which assesses how myasthenia gravis symptoms affect daily activities. The study included patients who are acetylcholine receptor autoantibody-positive (AChR+) and those who are muscle-specific kinase autoantibody-positive (MuSK+). The antibodies acetylcholine receptor and muscle-specific kinase can be found in the blood of people with myasthenia gravis.
Results from the study showed that Uplizna demonstrated clinically meaningful and statistically significant efficacy in both AChR+ and MuSK+ patients.
These results will be presented at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session during the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place October 15-18 in Savannah, Georgia.
Uplizna is already approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease of the central nervous system.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
